Citadel Advisors
HTGM

Citadel Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Citadel Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-70
Closed -$4K – 11737
2020
Q3 		$4K Buy
+70
New +$6.25K ﹤0.01% 9971

Other funds holding HTGM

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's HTGM Position: Q2 2021 in Review

Citadel Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2021, closing a stake of 1,568 shares — an estimated $103K sold.

Citadel Advisors first reported a position in HTGM in Q3 2016 and held it in 10 quarters. The position peaked at $216K in Q4 2018. 24 funds tracked by Wall St. Rank hold HTGM as of Q2 2021.

  • Citadel Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Citadel Advisors sold 1,568 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2021, an estimated $103K.
  • Citadel Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2016 and held it in 10 quarters.
  • Citadel Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $216K in Q4 2018.
  • 24 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.